FDA Recall Guanfacine Extended-release

The most recent Recall Enforcement Report that covers this product was initiated on March 31st, 2021 and classified as a Class II recall due to cross contamination with other product: product is being recalled due to trace amounts of quetiapine fumarate This recall is currently ongoing, and the associated recall number is recall number is D-0324-2021. It pertains to Guanfacine Extended-release identified by 60505-3929.

Recall Number D-0324-2021

Event ID

87648 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes).

Recall Number

D-0324-2021 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes).

Recall Classification

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified".

Distribution Pattern

Nationwide within the United States What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included.

Product Description

Guanfacine Extended-Release Tablets 2 mg,100-count bottles, Rx Only, Manufactured by: Apotex Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, Florida 33326, NDC 60505-3928-1, UPC 3 60505 39281 0

Reason For Recall

Cross Contamination with Other Product: Product is being recalled due to Trace Amounts of Quetiapine Fumarate What is the Reason for Recall?
Information describing how the product is defective.

Product Quantity

55620 bottles Product Quantity
The amount of product subject to recall.

Voluntary Mandated

Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order.

Report Date

04-14-2021

Recall Initiation Date

03-31-2021 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall.

Initial Firm Notification

Press Release Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall.

Product Type

Drugs

Recalling Firm

Apotex Corp.

Code Info/dt>

Lot #: RX1662, RX1663, RX1664 Exp. 11/2022 Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling.

Recalled NDC Packages

60505-3927-3; 60505-3927-1; 60505-3927-8; 60505-3928-3; 60505-3928-1; 60505-3928-8; 60505-3929-3; 60505-3929-1; 60505-3929-8; 60505-3930-3; 60505-3930-1; 60505-3930-8

Status

Ongoing

View Recall Report

What is the Enforcement Report?

All drug recalls are monitored by the Food and Drug Administration (FDA) and are included in the Enforcement Report once they are properly classified. The FDA will determine if a firm's removal or correction actions of a marked product meet the requirements to be considered a "recall". The FDA will also determine the public hazard assessment and a recall classification will be published in the Enforcement Report.